23 Jul, 2026
According to Straits Research, the global in vitro diagnostics market valued at $84.99 billion in 2025, is projected to grow from $90.23 billion in 2026 to $147.61 billion by 2034 at a CAGR of 6.35% during the forecast period 2026–2034.
The market growth is primarily attributed to the high burden of influenza cases, which continues to drive the demand for in vitro diagnostic (IVD) products for early detection and disease monitoring. For example, in May 2025, according to data from the Centers for Disease Control and Prevention (CDC), the 2024–2025 flu season recorded at least 47 million flu-related illnesses. Such a factor signifies the critical need for rapid and accurate diagnostic solutions. However, stringent product registration requirements limit the market access to companies, as in France. For a non-European manufacturer, there is a requirement for an authorized representative to be appointed for registration of IVD devices. This specific requirement hinders the availability of multiple products and, hence, market growth. Despite these challenges, the market presents significant opportunities, such as the growing network of domestic distribution of in vitro diagnostic kits, which presents as a significant market opportunity, with an increase in the availability of IVD kits. For instance, in June 2024, Cupid, a Nashik-based company, has expanded its distribution network for in vitro diagnostic kits across several Indian states, including Maharashtra, Goa, Gujarat, Rajasthan, Jammu & Kashmir, and Madhya Pradesh. Such regional expansion highlights a rising demand for reliable diagnostic solutions, driven by increasing healthcare awareness, public health initiatives, and the need for early disease detection.
sales@straitsresearch.com